This website uses cookies to improve your experience.

Cookie policy

Ondansetron for low anterior resection syndrome (LARS). A double-blind, placebo-controlled, cross-over, randomized study.

Popeskou SG, Roesel R, Faes S, Vanoni A, Galafassi J, di Tor Vajana AF et al.

Ann Surg 2024; 279: 196-202.

Thirty-four patients with symptomatic low anterior resection syndrome (LARS) were included. Those randomized to Ondansetron first had improved LARS scores, whereas those who had Ondansetron second, tended to have deteriorating scores. Treatment was safe.

Comment: Good treatment for an unpleasant condition.

Read paper


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery